uploads/2018/01/Mylan-Analysts-estimates-1.png

Analysts’ Recommendations for Mylan

By

Updated

Company overview

Mylan (MYL), which has a global presence, is focused on developing, manufacturing, and distributing generic, brand name, and over-the-counter products in various therapeutic categories. Mylan operates a vertically integrated manufacturing platform. According to the company, its product portfolio comprises more than 7,500 marketed products commercialized in more than 165 countries.

Article continues below advertisement

Analysts’ ratings

Of the 22 analysts covering Mylan in December 2017, 14 assigned it a “buy” or higher rating, and eight recommended “hold.” The mean rating for the stock is 2.1, and its mean target price is $44.10. Notably, Mylan makes up about 1.0% of the First Trust NASDAQ-100 Equal Weighted Index ETF (QQEW).

Peer ratings

In December 2017, of the 24 analysts covering Pfizer (PFE) in December 2017, 13 assigned it a “buy” or higher rating, and nine recommended “hold.” The mean rating for the stock is 2.5, and its mean target price is $38.29. Of the 23 analysts covering Merck (MRK), 13 assigned it a “buy” or higher rating, and ten recommended “hold.” The mean rating for the stock is 2.1, and its mean target price is $65.23. Of the 24 analysts covering Bristol-Myers Squibb (BMY), ten assigned it a “buy” or higher rating, and 12 recommended “hold.” The mean rating for the stock is 2.4, and its mean target price is $63.86. In the next part of this series, we’ll look at Mylan’s product portfolio.

Advertisement

More From Market Realist